BeiGene(BGNE)

Focus: BeiGene is a 10,000+ employee public biotechnology company headquartered in Beijing with a robust clinical pipeline focused on oncology and immunotherapy. The company operates as a mid-to-large cap biotech with global clinical trial infrastructure.

Profile data last refreshed 6h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Employees

10001+

Open Jobs

About BeiGene

AI assessmentNot Hiring

No open roles listed right now. Follow BeiGene to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

First line therapy

CLL/SLL

N/A

Lifirafenib

Solid Tumor, Adult

Phase 1

BGB-43395

Hormone-receptor-positive Breast Cancer

Help build intelligence for BeiGene

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline with 22 active programs across Phase 1-3, including 3 Phase 3 trials with near-term regulatory catalysts
Aggressive hiring across Clinical Operations (50 roles) and Commercial (47 roles) signals confidence in pipeline advancement and market expansion
Public company with NASDAQ listing (BGNE) offering equity upside and institutional stability with 10,000+ employee base

Watch Out For

Early-stage pipeline skewed toward Phase 1-2 (51 of 53 trials), limiting near-term revenue visibility and reducing job security tied to approvals
No disclosed financial metrics (revenue, R&D spend, cash position) creates transparency risk for career planning

Generated by Claude from BeiGene's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Clinical Trials (2)

NCT06761898A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants

Phase 1

NCT06253195BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1

dinutuximab beta

High-risk Neuroblastoma

Phase 1

Clinical Trials (1)

NCT05373901Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma

Phase 1

AMG 509

Prostate Cancer

Phase 1

PARP Inhibitor BGB-290

Glioblastoma

Phase 1

Clinical Trials (1)

NCT03749187BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Phase 1

BGB-45035

Healthy Participants

Phase 1

BGB-283

Solid Tumors

Phase 1

Clinical Trials (1)

NCT02610361Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

Phase 1

Drug: BG-T187

Advanced Solid Tumor

Phase 1

BGB-A317

Advanced Cancer

Phase 1

Clinical Trials (1)

NCT02407990Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Phase 1

BGB DXP593

Covid19

Phase 1

Clinical Trials (1)

NCT04532294Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Phase 1

BGB-290

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

Phase 1

Clinical Trials (4)

NCT03427814Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Phase 2

NCT03333915Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Phase 1/2

NCT02361723Phase 1a/1b BGB-290 for Advanced Solid Tumors.

Phase 1

+1 more

BGB-3111

Healthy Volunteers: Asian, Non-Asian

Phase 1

Clinical Trials (1)

NCT03301181Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

Phase 1

BGB-B455

Advanced Solid Tumor

Phase 1

BGB-283

Solid Tumors

Phase 1

Clinical Trials (1)

NCT03641586The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

Phase 1

[14C]-BGB-11417

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05844111A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417

Phase 1

BGB-11417

Mature B-cell Malignancies

Phase 1

[14C]-BGB-3111

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04163783Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

Phase 1

BGB-24714

Solid Tumor, Adult

Phase 1

BGB-30813

Advanced Solid Tumors

Phase 1

BGB-B167

Solid Tumors

Phase 1

BGB-A445

Advanced Solid Tumor

Phase 1

BGB-23339

Healthy Volunteers

Phase 1

Clinical Trials (2)

NCT05093270First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants

Phase 1

NCT05387668Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

Phase 1

zanidatamab

Gastric Cancer

Phase 1/2

BGB-16673

B-cell Malignancy

Phase 1/2

Clinical Trials (1)

NCT06776679A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants

Phase 1

PARP Inhibitor BGB-290

IDH1 Mutation

Phase 1/2

Clinical Trials (1)

NCT03914742BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Phase 1/2

BGB-11417

Acute Myeloid Leukemia

Phase 1/2

BGB-11417

Mantle Cell Lymphoma

Phase 1/2

Clinical Trials (1)

NCT05471843Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Phase 1/2

HIPEC

Gastric Cancer

Phase 2

sonrotoclax

Acute Myeloid Leukemia

Phase 2

Clinical Trials (2)

NCT06497062Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Phase 2

NCT06543043A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers

Phase 1

DKN-01

Gastric Cancer

Phase 2

lenvatinib

Hepatocellular Carcinoma

Phase 2

fruquintinib

Advanced Solid Tumors

Phase 2

BGB-11417

Leukemia

Phase 2

BGB-45035

Rheumatoid Arthritis

Phase 2

BGB-290

HER2-negative Breast Cancer

Phase 2

Clinical Trials (1)

NCT03575065Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Phase 2

pamiparib

Advanced Solid Tumors

Phase 2

Clinical Trials (5)

NCT04603365Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Phase 2

NCT03933761Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Phase 2

NCT03712930Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Phase 2

+2 more

BGB-DXP593

COVID-19

Phase 2

Clinical Trials (2)

NCT04551898Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Phase 2

NCT04669262BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

Phase 1

zanubrutinib

Mantle Cell Lymphoma

Phase 3

Clinical Trials (5)

NCT03734016A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase 3

NCT04002297A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Phase 3

NCT06547866Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia

Phase 2

+2 more

BGB-3111

Waldenström's Macroglobulinemia

Phase 3

Clinical Trials (1)

NCT03053440A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

Phase 3

tislelizumab

Non-Small Cell Lung Cancer

Phase 3

Clinical Trials (5)

NCT04746924A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Phase 3

NCT03777657Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Phase 3

NCT03924986Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)

Phase 3

+2 more

sitravatinib

Hepatocellular Carcinoma

Phase 3

Clinical Trials (1)

NCT04472650Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

Phase 1